Display options
Cite
Zucchelli E, Pema M, Stornaiuolo A, et al. Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Mol Ther Methods Clin Dev. 2017;4:102-114doi: 10.1016/j.omtm.2017.01.002.
Zucchelli, E., Pema, M., Stornaiuolo, A., Piovan, C., Scavullo, C., Giuliani, E., Bossi, S., Corna, S., Asperti, C., Bordignon, C., Rizzardi, G. P., & Bovolenta, C. (2017). Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Molecular therapy. Methods & clinical development, 4102-114. https://doi.org/10.1016/j.omtm.2017.01.002
Zucchelli, Eleonora, et al. "Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein." Molecular therapy. Methods & clinical development vol. 4 (2017): 102-114. doi: https://doi.org/10.1016/j.omtm.2017.01.002
Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C. Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17. PMID: 28344996; PMCID: PMC5363313.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17.

Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Molecular therapy. Methods & clinical development

Eleonora Zucchelli, Monika Pema, Anna Stornaiuolo, Claudia Piovan, Cinzia Scavullo, Erica Giuliani, Sergio Bossi, Stefano Corna, Claudia Asperti, Claudio Bordignon, Gian-Paolo Rizzardi, Chiara Bovolenta

Affiliations

  1. MolMed S.p.A., 20132 Milano, Italy; Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
  2. MolMed S.p.A., 20132 Milano, Italy.

PMID: 28344996 PMCID: PMC5363313 DOI: 10.1016/j.omtm.2017.01.002

Abstract

Lentiviral vectors (LVs) are a highly valuable tool for gene transfer currently exploited in basic, applied, and clinical studies. Their optimization is therefore very important for the field of vectorology and gene therapy. A key molecule for LV function is the envelope because it guides cell entry. The most commonly used in transiently produced LVs is the vesicular stomatitis virus glycoprotein (VSV-G) envelope, whose continuous expression is, however, toxic for stable LV producer cells. In contrast, the feline endogenous retroviral RD114-TR envelope is suitable for stable LV manufacturing, being well tolerated by producer cells under constitutive expression. We have previously reported successful, transient and stable production of LVs pseudotyped with RD114-TR for good transduction of T lymphocytes and CD34

Keywords: RD114-TR; RNA structure; codon optimization; envelope glycoprotein; gene therapy; gene vector delivery; gene vector engineering; lentiviral vector; packaging cell line

References

  1. Blood. 2002 Aug 1;100(3):823-32 - PubMed
  2. Nat Biotechnol. 2004 Nov;22(11):1393-8 - PubMed
  3. Nucleic Acids Res. 1987 Feb 11;15(3):1281-95 - PubMed
  4. Biotechnol J. 2011 Jun;6(6):650-9 - PubMed
  5. PLoS Comput Biol. 2010 Feb 05;6(2):e1000664 - PubMed
  6. Biochimie. 2003 Mar-Apr;85(3-4):295-301 - PubMed
  7. Hum Mol Genet. 2003 Feb 1;12(3):205-16 - PubMed
  8. Biochim Biophys Acta. 2000 Nov 10;1469(3):121-32 - PubMed
  9. Hum Gene Ther Methods. 2013 Aug;24(4):228-40 - PubMed
  10. Science. 2009 Apr 10;324(5924):255-8 - PubMed
  11. Nat Rev Genet. 2011 Aug 31;12(10):683-91 - PubMed
  12. J Virol. 1990 Sep;64(9):4264-73 - PubMed
  13. Trends Mol Med. 2014 Nov;20(11):604-13 - PubMed
  14. Science. 2006 Dec 22;314(5807):1930-3 - PubMed
  15. Blood. 2010 May 20;115(20):4021-9 - PubMed
  16. J Virol. 2004 Jul;78(13):7153-64 - PubMed
  17. J Gene Med. 2002 Jul-Aug;4(4):347-55 - PubMed
  18. J Gene Med. 2004 Feb;6 Suppl 1:S125-38 - PubMed
  19. Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66 - PubMed
  20. Hum Gene Ther. 2007 Sep;18(9):811-20 - PubMed
  21. Philos Trans R Soc Lond B Biol Sci. 2010 Apr 27;365(1544):1203-12 - PubMed
  22. Virology. 2000 Jul 20;273(1):60-6 - PubMed
  23. PLoS One. 2008 Jun 04;3(6):e2356 - PubMed
  24. Nat Rev Genet. 2002 Apr;3(4):285-98 - PubMed
  25. Mol Syst Biol. 2012 Feb 28;8:572 - PubMed
  26. Mol Ther Methods Clin Dev. 2016 May 11;3:16033 - PubMed
  27. Cell. 2010 Apr 16;141(2):344-54 - PubMed
  28. Sci Am. 2009 Jun;300(6):46-53 - PubMed
  29. J Mol Biol. 2008 Nov 7;383(2):281-91 - PubMed
  30. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4539-43 - PubMed
  31. Nat Rev Genet. 2006 Feb;7(2):98-108 - PubMed
  32. J Biotechnol. 2012 Dec 31;162(2-3):171-82 - PubMed
  33. Cell Host Microbe. 2012 Nov 15;12(5):623-32 - PubMed
  34. J Bioinform Comput Biol. 2005 Feb;3(1):157-68 - PubMed
  35. J Virol. 1999 Jun;73(6):4972-82 - PubMed
  36. Mol Ther. 2005 Mar;11(3):452-9 - PubMed
  37. J Biol Chem. 2010 Sep 10;285(37):28741-8 - PubMed
  38. Nat Biotechnol. 2003 May;21(5):569-72 - PubMed
  39. Trends Genet. 2000 Jul;16(7):287-9 - PubMed
  40. Hum Gene Ther. 2000 Nov 20;11(17):2403-13 - PubMed
  41. Immunology. 2007 Dec;122(4):522-31 - PubMed
  42. Protein Sci. 2010 Jul;19(7):1312-26 - PubMed
  43. Gene Ther. 2004 Mar;11(6):522-33 - PubMed
  44. BMC Evol Biol. 2010 Aug 19;10:253 - PubMed
  45. Nat Rev Genet. 2007 Oct;8(10):749-61 - PubMed
  46. Genome Res. 2004 Nov;14(11):2279-86 - PubMed
  47. PLoS One. 2011 Mar 03;6(3):e17596 - PubMed
  48. J Virol. 1992 Feb;66(2):906-13 - PubMed
  49. EMBO J. 2014 Jan 7;33(1):21-34 - PubMed

Publication Types